Affimed (AFMD) has released an update.
Affimed has reported encouraging results from their study, showing that their combination therapy of AFM24 and atezolizumab produced durable responses in heavily pretreated non-small cell lung cancer (NSCLC) patients. The therapy showed a manageable safety profile and suggests potential as an alternative treatment strategy for NSCLC patients resistant to existing therapies. The company continues to enroll patients in the study, with further updates expected later in the year.
For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.
